Fieldview Capital Management LLC Sells 7,572 Shares of Medpace Holdings, Inc. $MEDP

Fieldview Capital Management LLC cut its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 79.0% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,012 shares of the company’s stock after selling 7,572 shares during the quarter. Fieldview Capital Management LLC’s holdings in Medpace were worth $1,034,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Norges Bank acquired a new stake in Medpace during the 2nd quarter valued at $66,597,000. Clarkston Capital Partners LLC acquired a new position in shares of Medpace in the second quarter valued at $40,569,000. Mawer Investment Management Ltd. increased its holdings in shares of Medpace by 17.4% in the second quarter. Mawer Investment Management Ltd. now owns 817,432 shares of the company’s stock valued at $256,559,000 after purchasing an additional 121,213 shares during the last quarter. Bares Capital Management Inc. raised its position in shares of Medpace by 319.2% in the second quarter. Bares Capital Management Inc. now owns 157,084 shares of the company’s stock valued at $49,302,000 after purchasing an additional 119,608 shares during the period. Finally, JPMorgan Chase & Co. raised its position in shares of Medpace by 79.3% in the second quarter. JPMorgan Chase & Co. now owns 265,270 shares of the company’s stock valued at $83,258,000 after purchasing an additional 117,301 shares during the period. Institutional investors own 77.98% of the company’s stock.

Medpace Trading Up 1.7%

NASDAQ MEDP opened at $478.54 on Tuesday. The firm’s 50 day simple moving average is $532.11 and its 200 day simple moving average is $539.65. The firm has a market capitalization of $13.58 billion, a price-to-earnings ratio of 31.28, a P/E/G ratio of 2.26 and a beta of 1.44. Medpace Holdings, Inc. has a 1 year low of $250.05 and a 1 year high of $628.92.

Medpace (NASDAQ:MEDP) last released its quarterly earnings data on Monday, February 9th. The company reported $4.67 earnings per share for the quarter, beating the consensus estimate of $4.18 by $0.49. Medpace had a return on equity of 118.82% and a net margin of 17.83%.The business had revenue of $708.45 million for the quarter, compared to analyst estimates of $689.53 million. During the same period last year, the firm posted $3.67 earnings per share. Medpace’s revenue was up 32.0% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, equities research analysts forecast that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Analyst Ratings Changes

Several analysts recently commented on the stock. Mizuho set a $582.00 target price on shares of Medpace in a report on Wednesday, February 11th. Jefferies Financial Group raised shares of Medpace from a “hold” rating to a “buy” rating and set a $560.00 price target on the stock in a report on Friday, February 13th. Royal Bank Of Canada initiated coverage on shares of Medpace in a research report on Tuesday, March 3rd. They set an “outperform” rating and a $522.00 price objective for the company. TD Cowen upgraded Medpace from a “sell” rating to a “hold” rating and reduced their price objective for the stock from $462.00 to $419.00 in a report on Wednesday, February 18th. Finally, Weiss Ratings reaffirmed a “buy (b)” rating on shares of Medpace in a research report on Wednesday, January 28th. Five analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $486.67.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.